BUSINESS

Nihon Medi-Physics’ Project to Develop Labeled Antibody Therapeutics Selected for AMED’s CiCLE Grant Program

April 4, 2018

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

Nihon Medi-Physics announced on April 3 that its development project for labeled antibody therapeutics (alpha ray) and companion diagnostics has been selected by the Japan Agency for Medical Research and Development’s (AMED) Cyclic Innovation for Clinical Empowerment (CiCLE) grant program.…

To read the full story

With CiCLE Program Entering 2nd Year, AMED Should Release More Information on Grant Program
February 28, 2018
AMED Begins Taking Applications for Funding for Drug Discovery Environments
March 17, 2017

BUSINESS

Kyowa Kirin Halts Rocatinlimab Clinical Trials on Malignancy Concerns
March 4, 2026
Meiji’s Morcamilast Wins EU Orphan Tag for Palmoplantar Pustulosis
March 4, 2026
Efient AGs Launched Just Ahead of 3-Month Supply Deadline
March 4, 2026
Takeda Targets Psoriasis Market with Zasocitinib, Touts Edge in TYK2 Selectivity
March 4, 2026
Sumitomo Regains Growth Momentum, Eyes 350 Billion Yen from 2 Key Drugs in FY2028
March 3, 2026

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

G1 Rule to Hit Originator Biologics for First Time, Impact Seen for Up to 13 Brands

By Shinya Sato

Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…

COLUMN

The Strategic MSL: Beyond Data Delivery, It’s About Impact

By Philip Carrigan

I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…